BaseSpace
Correlation
Engine-Public
Sign In
Register
Correlation Engine 2.0
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
rs2476601
,
DNMT1
,
Angiogenesis
,
Allergy to pollen
,
Lymphocyte
,
Hematopoietic cell
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
4 1bb ligand
(compound)
Summary
General Info
Genetic Markers
Most Correlated Genes
No genes found
Explore Genetic Markers Results
Pathway Enrichment
Most Correlated Biogroups
No biogroups found
Explore Pathway Enrichment Results
Curated Studies
Most Correlated Studies
Melanoma specific antigen presenting CD8+ T cell clones with 4-1BBL expression
Monocytes from PBMCs of healthy donors cultured with agonistic CD137 mAb
Explore Curated Studies Results
Literature
Most Relevant Literature
Regulatory T Cells Inhibit T Cell Activity by Downregulating CD137 Ligand via CD137 Trogocytosis.
Secretion of 4-1BB Ligand Crosslinked to PD-1 Checkpoint Inhibitor Potentiates Chimeric Antigen Rece…
CD137 / CD137 ligand signalling regulates the immune balance: A potential target for novel immunothe…
Natural killer cells drive 4-1BBL positive uveal melanoma towards EMT and metastatic disease.
The CD137 Ligand Is Important for Type 1 Diabetes Development but Dispensable for the Homeostasis of…
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
A Study of ES101 (PD-L1x4-1BB Bispecific Antibody) in Patients With Advanced Malignant Thoracic Tumo…
Anti-CD137 and Anti-CTLA-4 Monoclonal Antibody in Patient With Advanced Cancer
Modified Melanoma Vaccine for High Risk or Low Residual Disease Patients
Neoadjuvant Nivolumab With and Without Urelumab in Cisplatin-Ineligible or Chemotherapy-refusing Pat…
Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ